Last updated 2026-07-20
- Raised Undisclosed Round led by SBI JI Innovation Fund, Sep 2017
Total raised
—
Last: Undisclosed Round 2017-10
Stage
Seed
Founded
2015
Headcount
19
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
ImmunoBrain Checkpoint (IBC) is a clinical-stage biopharmaceutical company focused on developing disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. The company's approach is based on over 25 years of research by Professor Michal Schwartz and her team at the Weizmann Institute of Science, who discovered the brain's dependence on the immune system for protection and repair. IBC's lead program, IBC-Ab002, is a proprietary anti-PD-L1 antibody being developed for the treatment of Alzheimer's disease.
Funding history · 1 round · — total
2017-09
Undisclosed Round
Undisclosed
★ SBI JI Innovation Fund
Headcount over time
From 9 (2018-09) to 19 (2026-03) · +10 (+111%) · 26 points · source: Finder history + radar grounding
Q&A
- What is ImmunoBrain Checkpoint's primary focus?
- ImmunoBrain Checkpoint is a biopharmaceutical company focused on developing disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways.
- What is ImmunoBrain Checkpoint's lead program targeting?
- ImmunoBrain Checkpoint's lead programs are being developed for the treatment of Alzheimer's disease, utilizing an approach of blocking the PD-1/PD-L1 immune checkpoint pathway.
- When was ImmunoBrain Checkpoint founded?
- ImmunoBrain Checkpoint was founded in February 2015.
- How many employees does ImmunoBrain Checkpoint have?
- ImmunoBrain Checkpoint has 19 employees, falling within the 11-50 employee bucket.
- What was a significant partnership for ImmunoBrain Checkpoint in 2017?
- In June 2017, Lundbeck, a global pharmaceutical company, obtained the rights to ImmunoBrain Checkpoint's research into Alzheimer's disease treatment. Lundbeck also provides funding for additional research and holds minority ownership with an exclusive option to take over the technology rights.
- Which investor participated in ImmunoBrain Checkpoint's funding round in October 2017?
- SBI JI Innovation Fund participated in ImmunoBrain Checkpoint's funding round in October 2017.
- What is ImmunoBrain Checkpoint's current funding stage?
- ImmunoBrain Checkpoint is currently in the Seed funding stage.
- Where is ImmunoBrain Checkpoint's headquarters located?
- ImmunoBrain Checkpoint's headquarters is located in Ness Ziona, Center District, Israel.
Team · 3
Michal Schwartz
Founder · Founder
Nathan Hevrony
Founder · Founder
Avraham Kadar
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Tags
brain-disorderbiopharmaceuticalneurosciencealzheimers-diseasebiotechnologyneurologyimmunologypharma-companiesimmunotherapypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunobrain.com/ |
|---|---|
| linkedin.com/company/10319109 |
Identifiers & details
| Legal name | ImmunoBrain Checkpoint Inc. |
|---|---|
| Founded | 2015 |
| Employees (exact) | 19 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | immunobrain.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515211860 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-02-16 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | פקריס 3 רחובות |